{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:51:27Z","timestamp":1793393487439,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SANAD Children\u2019s Cancer Support Association and SANAD Research Grants Program","award":["(Grant Number: RGP-2017- 02)"],"award-info":[{"award-number":["(Grant Number: RGP-2017- 02)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hodgkin lymphoma (HL) is lymphoid neoplasm usually affecting lymphatic system; it accounts 3.6% of cancers in Saudi Arabia. Modern treatment protocols had shown particular success rates in overall-survival (OS) and event-free-survival (EFS). In our study, we reviewed the medical records of 80 pediatric and young adolescent patients diagnosed HL from January 2006 to July 2020, treated at tertiary care hospital in Riyadh, Saudi Arabia. Demographic, clinical, and pathological data were explored. First line therapy was ABVD, COG, COPP, R-CHOP, or radiotherapy alone in 53\/80 (66.4%), 24\/80 (30%), 1\/80 (1.2%), 1\/80 (1.2%), or 1\/80 (1.2%) patients; respectively. Response assessment was done by CT\u2009+\u2009\/\u2009\u2212\u2009PET scan after first 2 cycles then every 2 cycle and end of therapy. Another assessment was done if any clinical suspicion of recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median age 11 (range 3\u201316) years. Males to females 1.3:1. Seventy-two out of eighty (90%) patients showed first complete remission (CR1) and maintained remission for median 40 (range 7\u2013136) months. Eight out of eighty (10%) patients showed refractory disease. Nineteen patients received salvage therapy (ICE or ESHAP\/brentuximab vedotin or gemcitabine\/brentuximab vedotin), 14\/19 (73.7%) had 2nd complete remission (CR2) for median time 24 (ranged 9\u201378) months, while 5\/19 (26.3%) did not show any response. Five-year OS and EFS were 95% and 75%. Two patients had 2ry malignant neoplasms, one had AML and died, the other had malignant fibrous histocytoma and still alive. None of our patients had fertility problem. Also, they did not experience chronic pulmonary or cardiotoxicity. Classic Hodgkin\u2019s lymphoma: nodular sclerosis subtype was more prominent (55%) than mixed cellularity subtype (22.5%), which is similar to several European and US studies, lymphocyte rich (11.25%) and lymphocyte depleted (0%), while nodular lymphocyte predominant Hodgkin\u2019s lymphoma (11.25%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study provided unique descriptive study of childhood HL, in Saudi Arabia, with valuable insight into the long-term outcome and late toxicity. Our results are comparable to other studies in the Middle East and European countries.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s43046-021-00078-0","type":"journal-article","created":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T23:03:21Z","timestamp":1629068601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinicopathologic features and therapy outcome in childhood Hodgkin\u2019s lymphoma: a report from tertiary care center in Saudi Arabia"],"prefix":"10.1186","volume":"33","author":[{"given":"Nawaf","family":"Alkhayat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9048-1386","authenticated-orcid":false,"given":"Mohammad","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaleb","family":"Elyamany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qanita","family":"Sedick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasna","family":"Hamzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Binhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Alshieban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour S.","family":"Aljabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaa","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneerah","family":"Alzouman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alsuhaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Elborai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"4","key":"78_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdf652","volume":"13","author":"RK Thomas","year":"2002","unstructured":"Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin\u2019s lymphoma. Ann Oncol. 2002;13(4):147\u201352. https:\/\/doi.org\/10.1093\/annonc\/mdf652.","journal-title":"Ann Oncol"},{"key":"78_CR2","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s12094-020-02297-8","volume":"22","author":"Y Elborai","year":"2020","unstructured":"Elborai Y, Elgammal A, Salama A, Fawzy M, El-Desouky ED, Attia I, et al. Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma. Clin Transl Oncol. 2020;22:1539\u201347. https:\/\/doi.org\/10.1007\/s12094-020-02297-8.","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"78_CR3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/1055-9965.1361.13.8","volume":"13","author":"ET Chang","year":"2004","unstructured":"Chang ET, Zheng T, Weir EG, Borowitz M, Mann RB, Spiegelman D, et al. Childhood social environment and Hodgkin\u2019s lymphoma: new findings from a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13(8):1361\u201370.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"78_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ijc.10164","volume":"98","author":"SL Glaser","year":"2002","unstructured":"Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF. Social class and risk of Hodgkin\u2019s disease in young-adult women in 1988\u201394. Int J Cancer. 2002;98(1):110\u20137. https:\/\/doi.org\/10.1002\/ijc.10164.","journal-title":"Int J Cancer"},{"issue":"2","key":"78_CR5","first-page":"141","volume":"43","author":"V Dinand","year":"2006","unstructured":"Dinand V, Arya LS. Epidemiology of childhood Hodgkin\u2019s disease: is it different in developing countries? Indian Pediatr. 2006;43(2):141\u20137.","journal-title":"Indian Pediatr"},{"issue":"4","key":"78_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59(4):225\u201349. https:\/\/doi.org\/10.3322\/caac.20006.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"78_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4103\/sjmms.sjmms_96_19","volume":"7","author":"H Alhashmi","year":"2019","unstructured":"Alhashmi H, Kandil M, Alhejazi A, Motabi I, Sagheir A, Alzahrani M, et al. Hodgkin\u2019s lymphoma: Saudi Lymphoma Group\u2019s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci. 2019;7(3):195\u2013201. https:\/\/doi.org\/10.4103\/sjmms.sjmms_96_19.","journal-title":"Saudi J Med Med Sci"},{"issue":"6","key":"78_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27684","volume":"66","author":"AF Belgaumi","year":"2019","unstructured":"Belgaumi AF, Pathan GQ, Siddiqui K, Ali AA, Al-Fawaz I, Al-Sweedan S, Ayas M, Al-Kofide AA. Incidence, clinical distribution, and patient characteristics of childhood cancer in Saudi Arabia: a population-based analysis. Pediatr Blood Cancer. 2019;66(6): e27684. https:\/\/doi.org\/10.1002\/pbc.27684.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"78_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524\u201348. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5688.","journal-title":"JAMA Oncol"},{"key":"78_CR10","doi-asserted-by":"publisher","unstructured":"Maggioncalda A, Malik N, Shenoy P, Smith M, Sinha R, Flowers CR. Clinical, molecular, and environmental risk factors for Hodgkin lymphoma. Adv Hematol. 2011:736261. doi: https:\/\/doi.org\/10.1155\/2011\/736261.","DOI":"10.1155\/2011\/736261"},{"issue":"5","key":"78_CR11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/pbc.20487","volume":"45","author":"A Oguz","year":"2005","unstructured":"Oguz A, Karadeniz C, Okur FV, Citak EC, Pinarli FG, Bora H, et al. Prognostic factors and treatment outcome in childhood Hodgkin disease. Pediatr Blood Cancer. 2005;45(5):670\u20135. https:\/\/doi.org\/10.1002\/pbc.20487.","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"78_CR12","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332. https:\/\/doi.org\/10.1182\/blood-2011-01-293050.","journal-title":"Blood"},{"issue":"11","key":"78_CR13","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Rosenberg RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: cotswolds meeting. J Clin Oncol. 1989;7(11):1630\u20136. https:\/\/doi.org\/10.1200\/JCO.1989.7.11.1630.","journal-title":"J Clin Oncol"},{"issue":"21","key":"78_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease: international prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med. 1998;339(21):1506\u201314. https:\/\/doi.org\/10.1056\/NEJM199811193392104.","journal-title":"N Engl J Med"},{"issue":"4","key":"78_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Lister JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1244.","journal-title":"J Clin Oncol"},{"key":"78_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3892\/ol.2011.255","volume":"2","author":"S Aquino","year":"2011","unstructured":"Aquino S, Clavio M, Rossi E, Vignolo L, Miglino M, Spriano M, et al. Therapy of Hodgkin\u2019s lymphoma in clinical practice: a retrospective long-term follow-up analysis. Oncol Lett. 2011;2:289\u201395. https:\/\/doi.org\/10.3892\/ol.2011.255.","journal-title":"Oncol Lett"},{"issue":"15","key":"78_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/MD.0000000000000670","volume":"94","author":"LM Sherief","year":"2015","unstructured":"Sherief LM, Elsafy UR, Abdelkhalek ER, Naglaa MK, Rabab E, Tamer HH, et al. Hodgkin lymphoma in childhood, clinicopathological features and therapy outcome at 2 centers from a developing country. Medicine. 2015;94(15):670\u20136. https:\/\/doi.org\/10.1097\/MD.0000000000000670.","journal-title":"Medicine"},{"issue":"2","key":"78_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/10428190802663205","volume":"50","author":"DC Stefan","year":"2009","unstructured":"Stefan DC, Stones D. How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk Lymphoma. 2009;50(2):196\u20139. https:\/\/doi.org\/10.1080\/10428190802663205.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"78_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/a:1008200210674","volume":"8","author":"F Baez","year":"1997","unstructured":"Baez F, Ocampo E, Conter V, Flores A, Gutierrez T, Malta A, et al. Treatment of childhood Hodgkin\u2019s disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol. 1997;8(3):247\u201350. https:\/\/doi.org\/10.1023\/a:1008200210674.","journal-title":"Ann Oncol"},{"key":"78_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/B978-0-7216-0081-9.50005-4","volume-title":"The Lymphomas","author":"AL Feldman","year":"2006","unstructured":"Feldman AL, Pittaluga S, Jaffe ES. Classification and histopathology of the lymphomas. In: Canellos GP, Lister TA, Young B, editors. The Lymphomas. 2nd ed. Philadelphia USA: Saunders Elsevier; 2006. p. 2\u201325.","edition":"2"},{"issue":"6","key":"78_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3109\/08880018.2013.823471","volume":"30","author":"A Pourtsidis","year":"2013","unstructured":"Pourtsidis A, Doganis D, Baka M, Bouhoutsou D, Varvoutsi M, Synodinou M, et al. Differences between younger and older patients with childhood Hodgkin lymphoma. Pediatr Hematol Oncol. 2013;30(6):532\u20136. https:\/\/doi.org\/10.3109\/08880018.2013.823471.","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"78_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/pbc.20157","volume":"46","author":"LS Arya","year":"2006","unstructured":"Arya LS, Dinand V, Thavaraj V, Bakhshi S, Dawar R, Rath GK, et al. Hodgkin\u2019s disease in Indian children: outcome with chemotherapy alone. Pediatr Blood Cancer. 2006;46(1):26\u201334. https:\/\/doi.org\/10.1002\/pbc.20157.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"78_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12308-010-0059-3","volume":"3","author":"J Audouin","year":"2010","unstructured":"Audouin J, Diebold J, Nathwani B, Ishak E, MacLennan K, Mueller-Hermelink H, et al. Epstein-Barr virus and Hodgkin\u2019s lymphoma in Cairo. Egypt J Hematop. 2010;3(1):11\u20138. https:\/\/doi.org\/10.1007\/s12308-010-0059-3.","journal-title":"Egypt J Hematop"},{"key":"78_CR24","unstructured":"Kamer Mutafo\u011flu Uysal, Riza \u00c7eting\u00f6z, Dilek G\u00fcne\u015f, Ay\u015fe Demiral, Erdener \u00d6zer, Handan \u00c7akmak\u00e7i, et al. Clinical characteristics and therapy outcome of pediatric Hodgkin\u2019s lymphoma - a single centre experience from the west part of Turkey. Turkish J Cancer\u00a02007;37(3):98\u2013108."},{"issue":"1","key":"78_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2006.08.036","volume":"43","author":"V Dinand","year":"2007","unstructured":"Dinand V, Dawar R, Arya LS, Unni R, Mohanty B, Singh R, et al. Hodgkin\u2019s lymphoma in Indian children: prevalence and significance of Epstein-Barr virus detection in Hodgkin\u2019s and Reed-Sternberg cells. Eur J Cancer. 2007;43(1):161\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2006.08.036.","journal-title":"Eur J Cancer"},{"issue":"10","key":"78_CR26","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1200\/JCO.2003.07.124","volume":"21","author":"RS Smith","year":"2003","unstructured":"Smith RS, Chen Q, Hudson MM, Link MP, Kun L, Billett HW, et al. Prognostic factors for children with Hodgkin\u2019s disease treated with combined-modality therapy. J Clin Oncol. 2003;21(10):2026\u201333. https:\/\/doi.org\/10.1200\/JCO.2003.07.124.","journal-title":"J Clin Oncol"},{"key":"78_CR27","doi-asserted-by":"publisher","unstructured":"Al Sayed Ahmed H, Raslan WF, Deifalla AHS, Fathallah MD. Overall survival of classical Hodgkins lymphoma in Saudi patients is affected by XPG repair gene polymorphism. Biomed Rep. 2019;10(1):10\u201316. doi:https:\/\/doi.org\/10.3892\/br.2018.1165.","DOI":"10.3892\/br.2018.1165"},{"key":"78_CR28","doi-asserted-by":"publisher","unstructured":"Alsultan A, Basher E, Alqanatish J, Mohammed R, Alfadhel M. Deficiency of ADA2 mimicking autoimmune lymphoproliferative syndrome in the absence of livedo reticularis and vasculitis. Pediatr Blood Cancer. 2018;65(4). doi: https:\/\/doi.org\/10.1002\/pbc.26912.","DOI":"10.1002\/pbc.26912"},{"issue":"1","key":"78_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10875-019-0590-7","volume":"39","author":"F Alabbas","year":"2019","unstructured":"Alabbas F, Elyamany G, Alsharif O, Hershfield M, Meyts I. Childhood Hodgkin lymphoma: think DADA2. J Clin Immunol. 2019;39(1):26\u20139. https:\/\/doi.org\/10.1007\/s10875-019-0590-7.","journal-title":"J Clin Immunol"},{"key":"78_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13039-019-0454-0","volume":"12","author":"N Alkhayat","year":"2019","unstructured":"Alkhayat N, Elyamany G, Elborai Y, Sedick Q, Al-Shahrani M, Al-Sharif O, et al. Rare cytogenetic abnormalities and their clinical relevance in pediatric acute leukemia of Saudi Arabian population. Mol Cytogenet. 2019;12:42\u201352. https:\/\/doi.org\/10.1186\/s13039-019-0454-0.","journal-title":"Mol Cytogenet"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-021-00078-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-021-00078-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-021-00078-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T11:51:01Z","timestamp":1673092261000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-021-00078-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1186\/s43046-021-00078-0","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institute review board (IRB), of Prince Sultan Military Medical City Riyadh Saudi Arabia, approved this retrospective study with committee\u2019s reference number 1390 (HP-01-R079).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}